Science News

VIENNA--(BUSINESS WIRE)--An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpaym...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation (“Aegis” or the “Company”) today announced it has named Joel Galanter Interim CEO, replacing Frank Basile who served as the company’s CEO since 2017. With more than a decade in senior executive leadership at Aegis, Galanter brings deep institutional knowledge and broad experience across the Company's operations, regulatory environment, and strategic priorities. Galanter has directly overseen the Company's legal, regulatory, governmen...

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ) clarifies its announcement that it has been awarded a $28 million contract extension, with an additional option of $30 million through the Defense Advanced Research Projects Agency (DARPA) It’s About Time program. Under the program, IonQ will advance its scalable clock production capabilities for its Evergreen-05 optical atomic clocks and deliver 125 units to U.S. government customers. The clocks are designed for mission-critical application...

PALO ALTO, Calif.--(BUSINESS WIRE)--Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). The award funds a research program to discover novel drug candidates for myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy (DMD). DMD is a rare genet...

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f...

DUBLIN--(BUSINESS WIRE)--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights....

PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 8,625,000 Class A ordinary shares at a price of $10.00 per share, including the 1,125,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Class A ordinary shares are listed on The Nasdaq Capital Market (“Nasdaq”) and began trading under the ticker symbol “TCGX” as of August 5, 2026. The Company is a special purp...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent u...

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we...